Benefit of Adding Panitumumab to FOLFOX4 in Patients with KRAS/NRAS Wild-Type (WT) Metastatic Colorectal Cancer (mCRC): A Number-Needed-To-Treat (NNT) Analysis
Jean‐Yves Douillard(Integrated Oncology (United States)), R. Sidhu(Amgen (United States)), S. Sienna(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Stephan Braun(Amgen (Switzerland)), Chris Davison(Amgen (United Kingdom))
Cited by 1
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
|The Lancet Oncology|2014|948